Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced a strategic refocusing of its research and development (R&D) portfolio following the expiration and termination of its option and license arrangements with PinCell S.r.l. related to the asset PC111. The decision, which took effect on Aug. 31, was not driven by any new negative scientific findings regarding PC111, according to the company. Instead, it allows Scinai to channel its R&D resources into its NanoAb platform while preserving capital and management capacity for its contract development and manufacturing organization (CDMO) business.
The company is advancing two IL-17 programs within the NanoAb platform, including an intradermal psoriasis program for which approximately €12 million in grant financing is under evaluation in Poland. This focus on NanoAb technology underscores Scinai’s commitment to developing innovative immunology therapies. Additionally, Scinai reported approximately $3.1 million in committed CDMO customer orders as of Aug. 16, and it continues to pursue approximately $5 million in CDMO revenue for 2026, subject to project execution, timing, revenue recognition, and additional business opportunities.
The strategic pivot is significant for Scinai as it seeks to balance its therapeutic development with a revenue-generating CDMO arm. By narrowing its R&D focus, the company aims to optimize its resources and potentially accelerate progress in its most promising areas. The CDMO business, which operates through Scinai Biopharma Services Ltd., provides development and manufacturing services to biotechnology and pharmaceutical companies from facilities in Jerusalem and Yavne, Israel. This dual approach—combining internal drug development with external manufacturing services—positions Scinai to generate near-term revenue while investing in long-term growth.
Investors and industry observers will likely watch how this refocusing impacts Scinai’s pipeline and financial performance. The decision to terminate the PinCell agreement, while not based on scientific concerns, frees up resources that can now be directed toward the NanoAb platform and CDMO expansion. The company’s ability to secure grant financing for its psoriasis program and grow its CDMO order book will be key indicators of its strategic execution.
For more details on the announcement, the full press release is available at https://ibn.fm/nnx0Z. Additional information about Scinai can be found in its newsroom at https://ibn.fm/SCNI.
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies. Its pipeline includes therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l. The company also owns a CDMO that provides development and manufacturing services to biotech and pharma companies. As Scinai navigates this strategic transition, its ability to leverage its NanoAb platform and CDMO services will be critical to its future success.
